GSK PLC 4Q Pre-items, Pretax Pft GBP1.56B

This headline was corrected at 0729 GMT to reflect GSK PLC 4Q Adj EPS 28.9p, not Adj EPS GBP1.551

By Joe Hoppe

GSK said its sales rose, driven by growth in its best-selling shingles vaccine Shingrix and the launch of RSV vaccine Arexvy earlier last year, and raised its guidance for 2024.
The British pharmaceutical major posted sales of 8.05 billion pounds ($10.22 billion) for the fourth quarter of 2023, up from GBP7.33 billion the year prior and beating a Visible Alpha consensus of GBP7.61 billion.
Write to Joe Hoppe at joseph.hoppe@wsj.com